Skip to main content

Table 2 Baseline clinical characteristics

From: Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension

 

Non–Down Syndrome

Down Syndrome

Parameter

n

Mean (SD)

n

Mean (SD)

mPAP, mm Hg

184

61.5 (23.0)

47

63.6 (16.7)

mSAP, mm Hg

184

75.3 (14.3)

47

67.9 (12.5)

RAP, mm Hg

184

8.3 (5.1)

47

7.5 (2.8)

mPAP/mSAP

184

0.8 (0.3)

47

0.9 (0.2)

PCWP, mm Hg

183

9.8 (3.8)

47

9.4 (2.9)

CI, L/min/m2

181

3.4 (1.5)

45

3.6 (2.3)

PVRI, dyn∙s/cm5/m2

177

1441.3 (1052.7)

45

1638.4 (1273.2)

SVRI, dyn∙s/cm5/m2

181

1822.4 (860.1)

45

1669.0 (852.6)

PVRI/SVRI

176

0.8 (0.7)

45

1.2 (1.3)

sPAP/sBP

184

0.9 (0.3)

47

0.9 (0.2)

dPAP/dBP

184

0.7 (0.3)

47

0.8 (0.2)

Peak VO2, mL/kg/min

113

18.4 (4.2)

2

12.4 (0.9)

Time to maximum peak VO2

113

466.7 (133.5)

2

445.0 (183.9)

% Predicted peak VO2

113

46.7 (11.4)

2

36.0 (5.1)

WHO Functional Class, n (%)

N = 183

 

N = 48

 

 Class I

57 (31)

 

18 (38)

 

 Class II

95 (52)

 

25 (52)

 

 Class III

30 (16)

 

5 (10)

 

 Class IV

1 (1)

 

0

 
  1. CI cardiac index, dBP diastolic blood pressure, dPAP diastolic pulmonary artery pressure, mPAP mean pulmonary artery pressure, mSAP mean systolic arterial pressure, PCWP pulmonary capillary wedge pressure, PVRI pulmonary vascular resistance index, RAP right arterial pressure, sBP systolic blood pressure, sPAP systolic pulmonary artery pressure, SVRI systemic vascular resistance index